US EditionTolebrutinib Study Strengthens Hope for Patients with Secondary Progressive Sclerosis
Summary by medicinsketidsskrifter.dk
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
MS JOURNAL New study strengthens hope for patients with secondary progressive sclerosis The BTK inhibitor tolebrutinib shows convincing results as a treatment for non-active secondary progressive sclerosis in a recently published study. It is a breakthrough that a treatment is now on the way for this patient group, says Chief Physician Jeppe Romme Christensen.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
